Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rodgers, M.
Right arrow Articles by Robertson, W.R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodgers, M.
Right arrow Articles by Robertson, W.R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 9, No. 4, pp. 638-642, 1994
© 1994 European Society of Human Reproduction and Embryology


other

Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal

M. Rodgers, J. McLoughlin, N. Peers, J. Anderson3, P. Woods2, G.G. Mitchell2 and W.R. Robertson1

Department of Clinical Biochemistry Manchester M20 8LR, UK 2Assisted Reproduction Unit, Hope Hospital Salford M6 8HD, Manchester M20 8LR, UK 3Department of Chemical Pathology, Withington Hospital Manchester M20 8LR, UK

Correspondence: 1To whom correspondence should be addressed

We examined the possible contribution of human chorionic gonadotrophin (HCG) in Pergonal to the serum luteinizing hormone (LH)-like bioactivity in 10 patients (median age32 years, range 28–38) with tubal infertility who were undergoing in-vitro fertilization (IVF), together with 19 controls (median age30 years, range 21–43). IVF patients were treated with clomiphene (50 mg twice daily) over days 2–6 and Pergonal (150 IU i.m.) daily from day 5 until at least day 10. Serum LH was measured by fluoro-immunometric assay (I-LH) and in-vitro Leydig cell bioassay (B-LH). Serum HCG was measured by fluoro-immunometric assay. The data were analysed by paired two-tailed t-test, following logarithmic transformation. From days 1–5, there was an increase in serum B-LH (mean, 95% confidence intervals given in parentheses) from 8.3 (6.8, 10.2) IU/1 to 11.7 (9.8, 13.9) IU/1 [P= 0.004], and in serum I-LH from 4.5 (3.7, 5.4) IU/1 to 5.4 (4.6, 6.3) IU/1 [P= 0.002]. From days 5–8, there was a rise in B-LH to 16.6 (12.6, 21.9) IU/1 [P= 0.023]. The rise in I-LH to 6.3 (5.1, 7.8) IU/1 [P= 0.081] failed to reach significance. Furthermore, serum HCG was <<0.75 IU/1 until after Pergonal was administered on day 5, then rose to a plateau on day 8 at 1.2(0.8, 1.6) IU/1. Serum HCG in the controls remained <<0.75 IU/1 throughout. We conclude there is a disproportionate increase in serum B-LH compared to I-LH from days 5–8, corresponding with a rise in serum HCG and the commencement of treatment with Pergonal. The HCG in Pergonal may be contributing to an undesirable rise in serum LH-like bioactivity, which might reduce the success rate of IVF.

Key words: bioactivity/HCG/HMG/IVF/LH


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
M. Filicori, G.E. Cognigni, P. Pocognoli, C. Tabarelli, D. Spettoli, S. Taraborrelli, and W. Ciampaglia
Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration
Hum. Reprod., August 1, 2002; 17(8): 2009 - 2015.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Filicori, G. E. Cognigni, S. Taraborrelli, D. Spettoli, W. Ciampaglia, C. Tabarelli de Fatis, P. Pocognoli, B. Cantelli, and S. Boschi
Luteinzing Hormone Activity in Menotropins Optimizes Folliculogenesis and Treatment in Controlled Ovarian Stimulation
J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 337 - 343.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.